← Russell 3000 cross-section

PSNL Personalis, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$1.9bn
Revenue TTM
$70m
Net income TTM
$-107m
Free cash flow
$-101m
Composite score
33.8
Sector rank
#1681

Valuation

P / E
EV / EBITDA
EV / sales
23.6
FCF yield
-5.43%
Earnings yield vs 10-yr
-10.50pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-153.8%
EBITDA margin
-150.1%
ROE
-45.6%
ROIC
-508.0%
Revenue growth
-13.3%

Insider activity, last 90 days

Net open-market
$-5.56m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

These increases were partially offset by (i) the expected revenue decline from Enterprise sales due to the completion of the project with Natera, and (ii) planned lower population sequencing revenue from the VA MVP. Components of Operating Results Revenue We derive our revenue primarily from sales of genomic testing services to the following five customer types: • Pharma testing services includes sales of testing services and data analytics for clinical trials and research to pharmaceutical companies in support of their oncology drug development programs. • Enterprise sales includes sales of tumor profiling and diagnostic tests directly to other businesses as an input to their products. …Personalis, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →